Get matched on WhatsApp
Tell us your concern and area. We'll shortlist additional verified clinics offering Weight Loss Injections.
Chat on WhatsAppComplete Guide
Weight Loss Injections in Malaysia
Mounjaro, Wegovy, Ozempic, Saxenda, Malaysia's weight loss injection market has transformed since 2023. This guide covers what's actually approved, what each drug does differently, real prices, and the counterfeit problem that's putting patients at serious risk.
Aug 2025
Mounjaro NPRA approved
Jan 2026
Wegovy launched Malaysia
RM1,400–3,200
Mounjaro monthly cost
48
MOH counterfeit warnings in 2025
Malaysia Has a Serious Counterfeit Weight Loss Injection Problem
In 2025, MOH Malaysia issued 48 warning letters related to counterfeit and unregistered GLP-1 medications. Malaysia has been identified by international health authorities as a major source of counterfeit semaglutide and tirzepatide products circulating in the black market. Counterfeit injectables have caused serious adverse events including hypoglycaemia, pancreatitis, and infections from unsterile products. Only obtain weight loss injections from a licensed doctor at a registered medical facility, never from Shopee, Lazada, Telegram channels, or unlicensed beauty centres.
Understanding
What Are GLP-1 Weight Loss Injections?
GLP-1 receptor agonists are a class of medications originally developed to treat Type 2 diabetes, discovered to produce dramatic weight loss as a secondary effect. The drugs work by mimicking hormones naturally released after eating, creating powerful appetite suppression and metabolic changes that make sustained weight loss achievable in a way diet and exercise alone often cannot match for patients with clinical obesity.
The result for most patients: significantly reduced appetite, reduced food intake without the psychological struggle typical of caloric restriction, and substantial, sustained weight loss, typically 10–20% of body weight over 6–12 months in clinical trials.
How They Work
- Slow gastric emptying, food moves through the stomach more slowly, increasing fullness
- Suppress appetite by acting on brain receptors that control hunger signals
- Reduce food cravings, particularly for high-calorie foods
- Improve insulin secretion in response to meals
- Reduce glucagon release (lowers blood glucose production by the liver)
Tirzepatide (Mounjaro) Difference
Tirzepatide is a dual GIP/GLP-1 receptor agonist, acting on both receptors simultaneously. Clinical trial data shows tirzepatide produces greater weight loss than semaglutide, average 22.5% body weight reduction vs. ~15% for semaglutide in head-to-head studies.
Medications
The Four Weight Loss Injections in Malaysia
Each medication has different approval status, efficacy data, dosing schedules, and pricing.
Mounjaro
Tirzepatide
Manufacturer: Eli Lilly
Mechanism: Dual GIP + GLP-1 receptor agonist
NPRA Status: Approved August 2025
Clinical Efficacy: SURMOUNT trial, average 22.5% body weight reduction at 72 weeks at highest dose
Dosing: Weekly injection. Starts at 2.5mg, titrated up to 15mg over several months. Self-administered subcutaneous injection (abdomen, thigh, or upper arm).
Price: RM1,400–3,200/month
Side Effects: Nausea (most common, typically mild and improves with dose titration), vomiting, diarrhoea, constipation, injection site reactions. Rare but serious: pancreatitis, gallbladder issues.
Best For: Patients wanting maximum clinical efficacy; patients with Type 2 diabetes alongside obesity; patients who have tried semaglutide with suboptimal results.
Wegovy
Semaglutide 2.4mg
Manufacturer: Novo Nordisk
Mechanism: GLP-1 receptor agonist
NPRA Status: Approved April 2023; officially launched in Malaysia January 2026
Clinical Efficacy: STEP trials, average 14.9% body weight reduction at 68 weeks
Dosing: Weekly injection. Starts at 0.25mg, titrated to 2.4mg over 16–20 weeks.
Price: RM1,200–2,500/month
Side Effects: Nausea, vomiting, diarrhoea, constipation, similar to other GLP-1 agonists.
Best For: Patients with established clinical obesity (BMI ≥30) wanting a well-evidenced, approved semaglutide option.
Key Distinction: Wegovy and Ozempic are both semaglutide, but Wegovy is formulated and approved at 2.4mg for weight management. Ozempic (max 2.0mg) is approved for diabetes management. Wegovy is the appropriate prescription for weight loss.
Ozempic
Semaglutide 0.5–2.0mg
Manufacturer: Novo Nordisk
Mechanism: GLP-1 receptor agonist
NPRA Status: Approved for Type 2 diabetes management, not officially indicated for weight loss
Clinical Efficacy: Weight loss of 5–10% at standard diabetes doses; significant weight loss at higher doses used off-label
Dosing: Weekly injection. Doses from 0.5mg to 2.0mg.
Price: RM800–1,800/month
Side Effects: Nausea, vomiting, diarrhoea, constipation.
Best For: Often more accessible than Wegovy given its established presence in the market.
Note: Many clinics prescribe Ozempic off-label for weight management. This is legal for doctors but patients should understand the regulatory context. Wegovy (the approved weight loss formulation) is now available and is the appropriate prescription for weight loss without diabetes.
Saxenda
Liraglutide
Manufacturer: Novo Nordisk
Mechanism: GLP-1 receptor agonist (older generation)
NPRA Status: Approved for weight management in Malaysia
Clinical Efficacy: SCALE trial, average 8% body weight reduction at 56 weeks. Less effective than semaglutide or tirzepatide.
Dosing: Daily injection (unlike weekly semaglutide/tirzepatide), self-administered subcutaneous injection.
Price: RM1,500–2,000/month
Side Effects: Nausea, vomiting, diarrhoea, constipation, injection site reactions.
Best For: Patients who cannot access or tolerate weekly injections; those with specific clinical reasons for liraglutide.
Note: Daily injection (vs. weekly for competitors), lower efficacy, and higher cost-per-outcome compared to Mounjaro and Wegovy.
Comparison
Comparing the Four Medications
| Mounjaro | Wegovy | Ozempic | Saxenda | |
|---|---|---|---|---|
| Drug name | Tirzepatide | Semaglutide 2.4mg | Semaglutide 0.5–2.0mg | Liraglutide |
| Mechanism | GIP + GLP-1 (dual) | GLP-1 | GLP-1 | GLP-1 |
| NPRA approval | Approved Aug 2025 | Approved 2023 (launched Jan 2026) | Diabetes only | Weight management |
| Injection frequency | Weekly | Weekly | Weekly | Daily |
| Avg weight loss (trials) | ~22.5% | ~14.9% | ~8–12% | ~8% |
| Price/month (Malaysia) | RM1,400–3,200 | RM1,200–2,500 | RM800–1,800 | RM1,500–2,000 |
| Primary use in Malaysia | Obesity + T2DM | Weight management | Diabetes (off-label weight) | Weight management |
Summary: Mounjaro currently has the strongest efficacy data of any approved weight loss medication in Malaysia, dual-receptor action produces meaningfully greater weight loss than GLP-1 monotherapy. Wegovy is the appropriate semaglutide option for weight management now that it has launched in Malaysia. Ozempic is a diabetes drug being used off-label. Saxenda remains an option for patients who cannot use weekly injections.
Patient Safety
The Counterfeit Problem: What Every Malaysian Patient Must Know
The Scale of the Problem
In 2025, the Malaysian Ministry of Health (MOH) issued 48 warning letters related to counterfeit and unregistered GLP-1 medications, a significant escalation from previous years. Malaysia has been identified by international health agencies as a major source of black-market semaglutide products.
What Counterfeits Look Like
- Products sold via Shopee, Lazada, Telegram channels, WhatsApp groups
- "Grey market" imports claimed to be from legitimate overseas pharmacies
- Products sold at beauty centres, slimming centres, or non-medical facilities
- Significantly below-market pricing on injections
- Products with packaging that looks authentic but contains wrong concentrations, wrong excipients, or non-pharmaceutical ingredients
Documented Harms
- Hypoglycaemia (dangerous blood sugar drops) from incorrect concentrations
- Pancreatitis from contaminated or wrongly formulated products
- Infections from non-sterile manufacturing
- No therapeutic effect from empty or diluted products
- Severe allergic reactions from unknown excipients
The Safe Path
Weight loss injections must be obtained from a licensed doctor at a registered MOH medical facility. The doctor should confirm NPRA registration of the product dispensed, provide proper medical assessment (BMI, comorbidities), monitor for side effects, and adjust dosing appropriately.
How to Verify
Ask your clinic to show you the product's NPRA registration certificate. Verify at bpfk.gov.my (National Pharmaceutical Regulatory Agency). The packaging should include a holographic NPRA sticker on authentic registered products.
Eligibility
Who Is Eligible? BMI Criteria and Assessment
| Criterion | Eligibility |
|---|---|
| BMI ≥ 30 | Eligible for all approved weight loss medications |
| BMI 27–29.9 with comorbidities | Eligible (comorbidities: T2DM, hypertension, sleep apnoea, dyslipidaemia) |
| BMI < 27 | Generally not indicated; assess with doctor |
| Type 2 Diabetes + obesity | All four medications potentially appropriate; Mounjaro specifically approved for T2DM |
| Previous weight loss attempts | Required by most protocols, medication is adjunct to lifestyle, not replacement |
What to Expect at a Proper Consultation
A qualified doctor will:
- Review your complete medical history and current medications
- Calculate BMI and assess for weight-related comorbidities
- Discuss realistic expectations, average 10–22% weight loss over 6–12 months with medication, lifestyle changes, and monitoring
- Explain the dose titration schedule and common side effects
- Schedule follow-up appointments to monitor progress and manage any side effects
Red flags at a consultation: no medical history review, no BMI assessment, no discussion of side effects, pressure to buy multiple months upfront, no follow-up plan.
Treatment Protocol
What to Expect: Starting a GLP-1 Medication
Month 1–2
Starting dose (e.g., Mounjaro 2.5mg weekly). Mild nausea is very common, usually manageable with small meals, eating slowly, and avoiding high-fat foods. Weight loss begins.
Month 2–4
Dose titration upward (based on tolerance and response). Nausea typically improves as body adjusts. Weight loss accelerates.
Month 4–6
Approaching or at target dose. Most significant weight loss phase.
Month 6–12
Continued weight loss and consolidation. Many patients reach 10–22% body weight reduction.
Ongoing
Long-term maintenance, weight loss medications work while you're taking them. Stopping typically leads to weight regain without sustained lifestyle changes.
Practical Guidance
- Eat smaller, lower-fat meals, GLP-1 medications slow gastric emptying; large or fatty meals worsen nausea
- Stay hydrated, reduced appetite can also reduce fluid intake
- Maintain protein intake, preserve muscle mass during weight loss
- Exercise, medications enhance fat loss; muscle mass is preserved better with resistance training
- Track progress monthly with your doctor, dose adjustments and monitoring are essential
Suitability
Who Is It For?
Good Candidates
- Adults with BMI ≥ 30 (clinical obesity)
- Adults with BMI 27–29.9 with weight-related health conditions
- Those who have made genuine diet and exercise efforts without adequate results
- Patients with Type 2 Diabetes needing both glycaemic and weight management
- Those wanting medical-grade weight management under doctor supervision
Not Suitable For
- Pregnant or planning pregnancy, GLP-1 medications are contraindicated
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- History of pancreatitis (relative contraindication, discuss with doctor)
- BMI below threshold without weight-related comorbidities
- Those seeking quick fixes without lifestyle commitment
- Anyone sourcing medications outside a licensed medical clinic
FAQ
Frequently Asked Questions
Common questions about weight loss injections in Malaysia.
Medical Disclaimer: This guide is for educational purposes only and does not constitute medical advice. Weight loss medications should only be prescribed by a licensed doctor after a thorough medical assessment. All treatment decisions should be made in consultation with a qualified healthcare professional. Always verify NPRA registration status of any medication. BookAClinic does not prescribe medications, dispense drugs, or provide medical consultations.